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ABSTRACT
New blood vessel sprouting (angiogenesis) and vascular physiology
are fundamental features of metazoan species but we do not fully
understand how signal transduction pathways regulate diverse
vascular responses. The vascular endothelial growth factor (VEGF)
family bind membrane-bound receptor tyrosine kinases (VEGFRs),
which trigger multiple signal transduction pathways and diverse
cellular responses.We evaluated whether theMAP3K family member
and proto-oncoprotein Tpl2 (MAP3K8) regulates basal and VEGF-A-
stimulated signal transduction in endothelial cells. Notably,
stimulation with exogenous VEGF-A increased Tpl2 mRNA levels
and consequently de novo protein synthesis. Depletion of Tpl2 levels
reveals a role in both basal and VEGF-A-stimulated endothelial cell
responses, including endothelial-leukocyte interactions, monolayer
permeability and new blood vessel formation. Under basal conditions,
Tpl2 modulates a signal transduction cascade resulting in
phosphorylation of a nuclear transcription factor (ATF-2) and
altered endothelial gene expression, a pathway previously identified
as crucial in VEGF-dependent vascular responses. Loss of Tpl2
expression or activity impairs signal transduction through Akt, eNOS
and ATF-2, broadly impacting on endothelial function. Our study now
provides a mechanism for Tpl2 as a central component of signal
transduction pathways in the endothelium.
KEY WORDS: Endothelial, VEGF-A, Tpl2, Signal transduction,
Angiogenesis
INTRODUCTION
Growth factors are soluble substances that bind plasma membrane
receptors and modulate cellular responses, tissue homeostasis, organ
development and animal physiology. Receptor-ligand complexes
exert such biological responses through activation of multiple signal
transduction pathways, which modulate cell and tissue function.
Receptor tyrosine kinases (RTKs) are a class of membrane-bound
receptors that regulate many aspects of cell and tissue function in
eukaryotes (Lemmon and Schlessinger, 2010). RTK function is
frequently linked to the activation of a canonical mitogen-activated
protein kinase (MAPK) pathway (Plotnikov et al., 2011). Different,
parallel MAPK-like signal transduction pathways can utilize
hierarchical arrays of closely related MAPK enzymes and opposing
protein phosphatases to regulate discrete biological processes. Such
cycles of phosphorylation and dephosphorylation regulate enzyme or
protein activity within different intracellular locations impacting on
metabolism, gene expression, cell migration and cell proliferation
(Katz et al., 2007). Although many well-established signal
transduction models exist from yeast to human, we still lack a full
understanding of how MAPK signal transduction pathways regulate
complex responses by primary cells or tissues.
The mammalian endothelium is a useful model for understanding
how signal transduction regulates complex biological responses e.g.
cell migration, cell proliferation and building vascular tubes
(Lammert and Axnick, 2012; Simons and Eichmann, 2015). The
endothelium is a terminally differentiated cell monolayer that lines
all blood vessels and responds to extrinsic factors such as
leukocytes, platelets, growth factors, lipids and pro-inflammatory
mediators (Muller, 2009). This is exemplified by the family of
vascular endothelial growth factors (VEGFs), which bind a specific
subfamily of RTKs (VEGFR1, 2 and 3) expressed by the
endothelium to regulate cell function, vascular and lymphatic
development (Koch and Claesson-Welsh, 2012; Smith et al.,
2015a). VEGF family members regulate biological processes such
as vasculogenesis, angiogenesis and lymphangiogenesis. The
founding member of this family, VEGF-A, binds VEGFR2 to
activate multiple signal transduction pathways that regulate
vasculogenesis and angiogenesis (Smith et al., 2015b). Such
intracellular signaling is essential for normal vascular function but
is subverted in tumor angiogenesis, a key feature of cancer initiation
and progression (Jain, 2014; Kieran et al., 2012).
VEGF-A binding to VEGFR2 activates the canonical MAPK
signal transduction pathway involving MEK1 and ERK1/2 (p42/44
MAPK) (Domigan et al., 2015; Simons and Eichmann, 2015; Smith
et al., 2015b). Furthermore, VEGF-A also activates other signal
transduction pathways leading to increased phosphorylation and
activation of Akt and p38 MAPK enzymes, which in turn impact on
nitric oxide levels, protein translation and cellular stress responses
(Fearnley et al., 2014a, 2016). A well-established paradigm in
cancer biology is that increased VEGF-A levels cause tumor
neovascularization leading to tumor growth and metastasis (Jain,
2014; Kieran et al., 2012; Vasudev and Reynolds, 2014). However,
blood vessels within tumors are often immature, tortuous, leaky and
prone to collapse under the elevated interstitial fluid pressure.
Normalization of the tumor vasculature represents a promising target
for anti-cancer therapy development. However, this relies on
identifying the critical signaling and transcriptional programs
controlling VEGF-dependent vascular leakage. In this study, we
investigated whether the Raf-related protein kinase, Tpl2 (MAP3K8),Received 14 March 2018; Accepted 5 April 2019
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plays a role in MAPK signal transduction and endothelial function.
We found that in primary human endothelial cells, VEGF-A
stimulates Tpl2 synthesis. Further analysis suggests Tpl2 is
functionally linked to MAPK signal transduction and nuclear gene
expression, which in turn influence cellular responses relevant for
angiogenesis and endothelial barrier integrity. Our study now
suggests a central role for Tpl2 in regulating endothelial function.
RESULTS
VEGF-A regulates Tpl2 expression and endothelial cell
responses
Gene expression profiling (https://www.ncbi.nlm.nih.gov/
geoprofiles/) suggests that the VEGF-A may regulate Raf-related
MAP3K family member and proto-oncogene, Tpl2 (MAP3K8)
expression (Schoenfeld et al., 2004; Schweighofer et al., 2009) with
more recent work implicating Tpl2 in angiogenesis (Lee et al.,
2013). One likelihood, based on VEGF-A-stimulated gene profiling
(Schoenfeld et al., 2004; Schweighofer et al., 2009) and VCAM-1
expression (Fearnley et al., 2014a), is that VEGF-A-stimulated
signal transduction promotes Tpl2 gene transcription and protein
expression. To test this idea, we stimulated primary human
umbilical vein endothelial cells (HUVECs) with VEGF-A for
different time periods and monitored Tpl2 protein levels in relation
to controls (Fig. 1A). Here, VEGF-A stimulation caused a relatively
rapid ∼2.5-fold increase in Tpl2 protein levels (doublet of 52 and
58 kDa) within 2 h and this effect was sustained over a 24 h period
(Fig. 1B). Analysis of mRNA levels revealed that VEGF-A
stimulation caused either ∼3.5-fold (1.5 h) or ∼2.5-fold (3 h)
increase in Tpl2 mRNA levels (Fig. 1C), preceding the changes in
Tpl2 protein levels.
VEGF-A stimulation of endothelial cells promotes distinct
patterns of gene expression and cellular responses (Fearnley et al.,
2014a; Matsumoto and Claesson-Welsh, 2001; Neagoe et al.,
2005). To assess whether Tpl2 plays a role in such VEGF-A-
regulated responses, we used RNA interference (RNAi) to assess
the functional requirement for Tpl2. Small inhibitory RNA (siRNA)
duplex-mediated knockdown caused noticeable decrease in
Tpl2 protein levels (Fig. 1D) corresponding to ∼60% reduction
(Fig. S1A). Knockdown of Tpl2 caused an inhibition in VEGF-A-
stimulated responses including ∼35% decrease in endothelial
tubulogenesis (Fig. 1E,F) and ∼45% decrease in endothelial–
leukocyte interactions (Fig. 1G,H). Furthermore, Tpl2 knockdown
caused ∼20% decrease in endothelial cell viability (Fig. S1B).
These data suggest that Tpl2 regulates both cell viability and
VEGF-A-stimulated endothelial responses.
Tpl2 levels regulate ATF-2 phosphorylation, turnover
and function
Tightly regulated expression of vascular cell adhesion molecule 1
(VCAM-1) on endothelial cells influences leukocyte binding to
the activated endothelium (Nourshargh et al., 2010). Previous
studies have shown that VEGF-A stimulates endothelial VCAM-1
expression via the canonical MEK1-ERK1/2 signaling pathway and
hyperphosphorylation of nuclear activating transcription factor 2
(ATF-2) (Fearnley et al., 2014a). Knockdown of Tpl2 levels and the
significant decrease in VEGF-A-stimulated endothelial-leukocyte
interactions (Fig. 1G,H) raised the possibility that Tpl2 regulates the
signal transduction pathway leading to ATF-2 hyperphosphorylation
and VCAM-1 expression. To address this, RNAi was used to
knockdown either endothelial ATF-2 or Tpl2 prior to stimulation
with two VEGF-A isoforms (VEGF-A165 and the less bioactive
VEGF-A121) followed by immunoblotting (Fig. 2). VEGF-A165 but
not VEGF-A121 stimulation increased VCAM-1 protein levels after
4 h (Fig. 2A). Consequently, we focused on VEGF-A165-stimulated
endothelial responses for further investigation.
Elevated VCAM-1 levels were associated with the presence of
phosphorylated ATF-2 (p-ATF-2) and Tpl2 as depletion of either
ATF-2 or Tpl2 prevented VEGF-A-stimulated increases in
VCAM-1 expression (Fig. 2A). Although VEGF-A stimulation
caused a >four-fold rise in VCAM-1 levels (Fig. 2B), Tpl2
knockdown reduced VCAM-1 expression close to baseline levels
(Fig. 2B). This effect was comparable to the decreased VCAM-1
levels caused by ATF-2 depletion (Fig. 2B). Notably, ATF-2
depletion also caused ∼two-fold increase in Tpl2 levels under basal
conditions in the presence of relatively low VEGF-A levels
(≤0.5 ng/ml) with loss of VEGF-A-stimulated increase in Tpl2
levels (Fig. 2C). Surprisingly, analysis of phospho-ATF-2 (pT71)
showed that Tpl2 depletion caused a significant decrease in basal
and VEGF-A-stimulated levels (Fig. 2D). There was a similar
∼70% in total ATF-2 levels (Fig. 2E). Such findings suggested a
functional link between Tpl2 and ATF-2.
To further investigate how Tpl2 and ATF-2 were linked, we
treated endothelial cells with the small molecule Tpl2-selective
kinase inhibitor CAS 871307-18-5 (IC50 ∼50 nM) and assessed
effects on signal transduction and VCAM-1 expression (Fig. 3).
Endothelial cells were subjected to a time course of treatment with
2 µM Tpl2-selective kinase inhibitor (Fig. 3A), prior to
quantification of relative levels of phospho-ATF-2 (Fig. 3B) and
Tpl2 (Fig. 3C). Treatment with Tpl2-selective kinase inhibitor
caused a relatively rapid reduction in ATF-2-pT71 levels but did not
affect total ATF-2 levels (Fig. 3A); this ∼60% decrease in phospho-
ATF2 persisted up to 8 h (Fig. 3B). Tpl2-selective kinase inhibitor
treatment also caused a gradual rise in Tpl2 levels (Fig. 3A,C)
with ∼60% increase in Tpl2 levels evident after 4 h (Fig. 3C). We
then tested increasing concentrations of Tpl2-selective kinase
inhibitor for 4 h and again found that ATF-2-pT71 levels were
substantially reduced (Fig. 3D,E). Notably, total ATF-2 levels were
substantially depleted by ∼50% when Tpl2-selective kinase
inhibitor concentration was >25 µM (Fig. 3D,F).
VEGF-A-stimulated phosphorylation of ATF-2 correlates with
elevated VCAM-1 expression (Fig. 2D versus B). Furthermore,
Tpl2 depletion impaired VEGF-A-stimulated VCAM-1 expression
(Fig. 2B). To investigate the link between Tpl2 kinase activity
and VEGF-A-stimulated signaling, we pre-treated endothelial cells
with Tpl2-selective kinase inhibitor, (2 µM, 30 min) prior to VEGF-A
isoform stimulation (Fig. 3G). Here, treatment with Tpl2-selective
kinase inhibitor caused a clear reduction in VEGF-A-stimulated
VCAM-1 expression (Fig. 3G) corresponding to a ∼38% decrease in
VCAM-1 levels (Fig. 3H). These data show Tpl2 requirement in both
ATF-2phosphorylation andVEGF-A-stimulatedVCAM-1expression.
Tpl2 is functionally linked to angiogenesis
Our initial findings presented in this study (Fig. 1) indicated
Tpl2 expression is required for VEGF-A-regulated endothelial
tubulogenesis, a key feature of angiogenesis. To determine the
effects of the Tpl2-selective kinase inhibitor on VEGF-A-stimulated
endothelial tubulogenesis and aortic sprouting (Fig. 4). Here,
Tpl2-selective kinase inhibitor treatment caused a substantial
reduction in VEGF-A-stimulated endothelial tubulogenesis
(Fig. 4A) corresponding to ∼50% decrease in VEGF-A-stimulated
endothelial tubule length (Fig. 4B). Using a mouse aortic sprouting
assay, Tpl2-selective kinase inhibitor also reduced VEGF-A-
stimulated endothelial sprout formation (Fig. 4C) with a ∼five-fold
reduction (Fig. 4D). Treatment with Tpl2-selective kinase inhibitor
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Fig. 1. See next page for legend.
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had no significant effect on non-stimulated (basal) tubulogenesis
(Fig. 4B) or aortic sprouting in the absence of VEGF-A (Fig. 4D).
These data further support a role for Tpl2 in regulating VEGF-A-
stimulated angiogenesis.
Tpl2 regulates signal transduction and endothelial cell
permeability
Endothelial cell permeability is a tightly controlled process for
normal vascular physiology and can combat pathological conditions
e.g. blood vessel damage (Mehta and Malik, 2006; Trani and
Dejana, 2015). One regulatory mechanism that controls vascular
permeability is VEGF-A-regulated activation of endothelial nitric
oxide synthase (eNOS) (Lal et al., 2001; Six et al., 2002). VEGF-A-
stimulated signal transduction promotes Akt phosphorylation and
elevated Akt kinase activity, which in turn phosphorylates and
activates eNOS leading to elevated NO levels (Dimmeler et al.,
1999; Lal et al., 2001; Six et al., 2002). The NO molecule acts as a
rapidly diffusible second messenger that promotes endothelial
monolayer permeability (Di Lorenzo et al., 2013; Lal et al., 2001;
Six et al., 2002).
Tpl2 kinase activity is implicated in Akt phosphorylation and
activation (López-Peláez et al., 2011; Li et al., 2015), suggesting
that endothelial Tpl2 could regulate eNOS status and endothelial
monolayer permeability. To investigate this further, we analyzed
Akt and eNOS phosphorylation and overall levels in control or
Tpl2-depleted endothelial cells (Fig. 5A). Quantification of these
data showed that Tpl2 depletion caused a ∼50% decrease in relative
levels of phospho-Akt (Akt-pS473) (Fig. 5B). Furthermore, Tpl2
depletion also caused a ∼30% decrease in relative levels of
phospho-eNOS (Fig. 5C). To check for the influence of other signal
transduction pathways, small molecule kinase inhibitors specific for
ERK1/2 (PD98059; IC50, 1-20 µM), p38 MAPK (SB203580; IC50,
500 nM), JNK (SP600125; IC50, 100-150 nM) or Akt (MK2206;
IC50, 8-65 nM) were tested and phospho-Akt and phospho-eNOS
levels evaluated (Fig. S2A). Quantification of these data showed
that Akt inhibition by MK2206 caused a ∼40% decrease in relative
levels of phospho-eNOS compared to control; pharmacological
inhibition of EKR1/2, p38 MAPK or JNK had little or no effect
(Fig. S2B). Thus under basal conditions, Tpl2 influences Akt and
eNOS phosphorylation.
To assess whether Tpl2-mediated regulation of Akt and eNOS
status had a functional effect on endothelial cell permeability, we
measured a parameter called trans-endothelial electrical resistance
(TEER). Under basal (non-stimulated) conditions, Tpl2-depleted
endothelial cells exhibited a ∼30% increase in relative TEER value
(indicating decreased cell monolayer permeability) compared to
control (Fig. 5D). Upon VEGF-A stimulation however, we observed
a time-dependent oscillation in relative TEER values (Fig. 5E).
Within 1 h of VEGF-A stimulation, endothelial cells exhibited a
transient rise in relative TEER values for control, scrambled and
Tpl2 siRNA-treated endothelial cells (Fig. 5E). This was followed
by a gradual decrease in TEER values over the next 7 h of VEGF-A
treatment, consistent with an increase in endothelial cell
permeability (Fig. 5E). The decrease in TEER values was more
pronounced in controls and scrambled siRNA-treated cells over
time, compared to Tpl2-depleted endothelial cells (Fig. 5E). Thus
Tpl2 contributes to VEGF-A-stimulated increase in endothelial
monolayer permeability.
Importantly, Tpl2 depletion caused increased expression of
endothelial cell junctional proteins VE-cadherin and PECAM-1
(Fig. 6A). However, there were no significant changes in expression
of another endothelial cell surface marker and adhesion protein,
PVR (CD155), upon Tpl2 depletion (Fig. 6A). Nectin 2 is another
cell surface membrane glycoprotein that is part of the adherens
junction complex: Tpl2 depletion did not significantly affect
expression of this protein (Fig. 6B). Under conditions of Tpl2
depletion, and elevated PECAM-1 levels, there was some changes
in F-actin staining (Fig. 6B).
It is feasible that Tpl2 regulates multiple signal transduction
pathways. This could be relevant in this study as multiple signal
transduction pathways including ERK1/2, p38 MAPK and JNK are
implicated in ATF-2 phosphorylation (Lau and Ronai, 2012). To
assess whether other signaling pathways are linked to Tpl2 regulated
ATF-2 hyperphosphorylation and turnover, we assessed whether
Tpl2-selective kinase inhibitor titration affected ERK1/2, p38
MAPK, JNK and Akt phosphorylation (Fig. 7A). As previously
observed, Tpl2-selective kinase inhibitor caused a 30–40%
reduction in phospho-Akt levels (Fig. 7B) but no significant
effects on ERK1/2, p38 MAPK or JNK phosphorylation were
evident (Fig. 7C–E). We then assessed whether small molecule
inhibitors specific for ERK1/2 (PD98059), p38 MAPK
(SB203580), JNK (SP600125) or Akt (MK2206) affected ATF-2
status (Fig. 7F). These inhibitors blocked target kinase
phosphorylation as expected but did not affect ATF-2-pT71 or
ATF-2 levels (Fig. 7F). Quantification of these data confirmed
inhibition of these different signal transduction pathways did not
significantly affect phospho-ATF-2 levels (Fig. 7G).
DISCUSSION
The endothelial response to soluble factors such as VEGF-A
regulates vasculogenesis and angiogenesis, important processes in
health and disease (Jain, 2014; Smith et al., 2015b). Our study
investigated the requirement for the proto-oncoprotein and MAP3K
family member, Tpl2 (MAP3K8), in signal transduction and
associated cellular responses in primary endothelial cells. Our
findings now provide a role for Tpl2 in integrating multiple signal
transduction pathways in regulating endothelial function (Fig. 8).
Tpl2 is required for VEGF-A-stimulated endothelial
cell responses
A central finding of our study is that VEGF-A-stimulated signal
transduction pathways are linked to Tpl2 in endothelial cell
responses. First, Tpl2 depletion reduces VEGF-A-stimulated
endothelial tubulogenesis, which is a key requirement for
angiogenesis. Second, treatment with a Tpl2-selective kinase
inhibitor impaired both VEGF-A-stimulated endothelial
tubulogenesis and aortic sprouting, further supporting functional
requirement for Tpl2 in VEGF-A-stimulated angiogenesis. Third,
Fig. 1. VEGF-A-stimulated Tpl2 expression modulates endothelial cell
responses. (A) Endothelial cells stimulated with VEGF-A (25 ng/ml)
for 2, 4, 6, 8 or 24 h were lysed and subjected to immunoblot analysis.
(B) Quantification of VEGF-A-stimulated changes in relative Tpl2 protein
levels using immunoblotting data. Error bars indicate ±s.e.m. (n=6).
Statistical test=one-way ANOVA; *P<0.05, **P<0.01. (C) Endothelial cells
stimulated with VEGF-A (25 ng/ml) for 1.5 or 3 h prior to quantification of
relative Tpl2 mRNA levels using qRT-PCR. Error bars indicate ±s.e.m.
(n=3). Statistical test=one-way ANOVA; **P<0.01, ****P<0.0001.
(D) Immunoblot analysis of control (mock-transfected), scrambled
siRNA-treated or Tpl2-depleted endothelial cells (E–H). Control (mock-
transfected), scrambled or Tpl2-depleted endothelial cells were stimulated
with VEGF-A (25 ng/ml), processed with different assays (see Materials
and Methods) and quantified for cellular responses in (E,F) endothelial
tubulogenesis, or (G,H) endothelial-leukocyte interactions. Scale bars:
1000 µm. Error bars indicate ±s.e.m. (n=3). In panels F and H, statistical
tests=two-way ANOVA; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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Fig. 2. Tpl2 is required for VEGF-A-stimulated ATF-2-dependent VCAM-1 expression. (A) Control, scrambled, Tpl2 or ATF-2-specific siRNA-treated
endothelial cells were stimulated (25 ng/ml) with either VEGF-A165 or VEGF-A121 (negative control) for 4 or 8 h, prior to immunoblot analysis. (B–E) Quantification
of protein levels by immunoblot analyses (see the Materials and Methods) of VEGF-A (25 ng/ml) stimulated control, scrambled, Tpl2-depleted or ATF-2 depleted
endothelial cells for protein levels of (B) VCAM-1, (C) Tpl2, (D) ATF-2-pT71 and (E) ATF-2. Error bars indicate ±s.e.m. (n=3). In panels B–E, statistical
tests=two-way ANOVA; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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Tpl2 depletion reduced endothelial-leukocyte interactions, showing
Tpl2 contributes to the regulation of cell–cell interactions (Fig. 8).
Finally, Tpl2 levels modulated Akt and eNOS activity, which
affectedmonolayer permeability (Fig. 8). Our findings implicate Tpl2
as a key signaling component in endothelial cells, which impact on
VEGF-A-stimulated angiogenesis and vascular control. This study
complements previous observations that pharmacological inhibition
of Tpl2 impairs tumor-associated angiogenesis, blood vessel
formation in vivo and VEGF-A-stimulated endothelial cell
responses (Lee et al., 2013).
Tpl2 requirement in in basal signal transduction pathways
Our study provides several lines of evidence for Tpl2 regulation of
basal signal transduction events impacting on endothelial cell
function and homeostasis. Firstly, Tpl2 depletion or treatment with
a Tpl2-selective inhibitor reduces both phospho- and steady-state
ATF-2 levels, with a concomitant loss in VEGF-A-stimulated
VCAM-1 expression. Previously it had been shown that VEGF-A
and ATF-2 were part of a signaling pathway that controls VCAM-1
expression (Fearnley et al., 2014a), thus arguing that VEGF-A, Tpl2,
ATF-2 and VCAM-1 are functionally linked to control signal
Fig. 3. Tpl2-selective kinase inhibitor treatment attenuates ATF-2 phosphorylation and expression levels. (A–F) Analysis of basal endothelial signaling
in non-stimulated cells. (A) Immunoblot analysis of endothelial cells treated with Tpl2-selective kinase inhibitor (2 µM) for 0, 1, 2, 4 or 8 h to assess effects on
VEGFR2, ATF-2 and Tpl2 status. Quantification of immunoblot data for Tpl2-selective inhibitor time course for (B) ATF-2-pT71, and (C) Tpl2 levels. Error
bars indicate ±s.e.m. (n=4). In panels B and C, statistical tests=one-way ANOVA; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. (D) Immunoblot analysis of
endothelial cell response to Tpl2-selective kinase inhibitor titration (2–50 µM, 4 h). (E,F) Quantification of immunoblot data from Tpl2-selective kinase inhibitor
titration on (E) ATF-2-pT71, and (F) ATF-2 levels. Error bars indicate ±s.e.m. (n=3). In panels E and F, statistical tests=one-way ANOVA; *P<0.05, **P<0.01.
(G) Endothelial cells were pre-treated with a Tpl2-selective kinase inhibitor (2 µM; 30 min) prior to stimulation with either (25 ng/ml) VEGF-A165 (165) or
VEGF-A121 (121, negative control) for 0 or 8 h before lysis and immunoblot analysis. (H) Quantification of immunoblot data showing changes in relative
VCAM-1 levels upon VEGF-A (25 ng/ml) treatment in the absence (−) or presence (+) of Tpl2 kinase inhibitor. Error bars indicate ±s.e.m. (n=6). Statistical
test=two-way ANOVA; *P<0.05, **P<0.01, ****P<0.0001.
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transduction and gene expression. How Tpl2 modulates ATF-2
phosphorylation is unclear; however, one explanation is that Tpl2
phosphorylates and activates ERK1/2 (Banerjee et al., 2006; Dumitru
et al., 2000), and phospho-ERK1/2 targets T71 residue on ATF-2 for
phosphorylation (Lau and Ronai, 2012). Phosphorylation of T71 on
ATF-2 blocks ubiquitination and subsequent degradation by the 26S
proteasome (Fuchs et al., 2000), thus stabilizing its steady state levels.
However, pharmacological inhibition of ERK1/2 has little effect
on ATF-2-pT71 levels, suggesting differences in endothelial Tpl2
regulation of such events. Alternatively, as Tpl2 can be detected in
the nucleus (Kanellis et al., 2015), activated Tpl2 could directly
phosphorylate nuclear ATF-2. Our model provides a role for the Tpl2
kinase in communicating to both nuclear (ATF-2) and cytoplasmic
effectors (e.g. Akt) (Fig. 8).
Many studies have documented the close link between Tpl2 and
NF-κB with conflicting views as to whether Tpl2 activates or
suppresses NF-κB activation (Vougioukalaki et al., 2011).
Interleukin 1β activates endothelial NF-κB whereas VEGF-A
does not behave similarly (Schweighofer et al., 2007); however,
other studies suggest that VEGF-A does indeed activate NF-κB
(Maeng et al., 2006). Nonetheless, genetic ablation of Tpl2 in
astrocytes down-regulates VCAM-1 expression in response to
ligands such as TNFα and bacterial lipopolysaccharide that
classically activate the NF-κB pathway (Sriskantharajah et al.,
2014), suggesting that Tpl2 and ATF-2 may be functionally linked
in other cell types.
Our study shows that Tpl2 levels modulate both Akt and eNOS
phosphorylation and activation, which further impacts on resting
and VEGF-A-stimulated endothelial monolayer permeability.
Depletion of Tpl2 levels causes a rise in relative TEER values,
indicative of decreased endothelial permeability. Our finding that
Tpl2 depletion causes elevated expression of adhesion proteins such
as VE-cadherin and PECAM-1, key regulators of endothelial cell–
cell monolayer integrity, could explain the increased cell–cell
adhesion and decreased permeability. Interestingly, macrophages
from Tpl2-null mice display reduced phospho-Akt levels (López-
Peláez et al., 2011) and similarly in the liver (Li et al., 2015). Our
studies provide the basis for functionally linking Tpl2 to surface
adhesion proteins that regulate endothelial monolayer integrity and
permeability.
VEGF-A-regulated Tpl2 synthesis promotes signal
transduction and cellular responses
One finding from our study is that exogenous VEGF-A stimulates
new Tpl2 synthesis with a four-fold rise in Tpl2 mRNA levels
promoting a 2.5-fold rise in Tpl2 protein levels. Our work now
Fig. 4. Tpl2-selective kinase inhibitor treatment impairs VEGF-A-stimulated endothelial cell tubulogenesis and aortic sprouting. (A) Endothelial
cells co-cultured with primary human fibroblasts were stimulated with VEGF-A (25 ng/ml)±Tpl2-selective kinase inhibitor (2 µM). Endothelial cell tubules were
fixed and stained for the Tpl2-selective kinase endothelial cell-specific marker and cell adhesion molecule (PECAM-1) for visualization using fluorescence
microscopy. (B) Quantification of endothelial tubule length from fluorescence microscopy datasets. Error bars indicate ±s.e.m. (n=3). Statistical test=two-way
ANOVA; *P<0.05, **P<0.01, ***P<0.001. (C) Endothelial sprouting from mouse aortic slices stimulated with VEGF-A (25 ng/ml)±2 µM Tpl2-selective kinase
inhibitor followed by fixation, staining with FITC-conjugated endothelial-specific lectin (see the Materials and Methods) and visualization using fluorescence
microscopy. (D) Quantification of endothelial sprout number from mouse aortas upon treatment with VEGF-A±Tpl2, selective kinase inhibitor. Error bars
indicate ±s.e.m. (n≥4). Statistical test=two-way ANOVA; ***P<0.001, ****P<0.0001. Scale bars: 1000 µm.
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shows that resting or basal Tpl2 levels influences phosphorylation
of Akt and ATF-2 and downstream targets such as eNOS and the
nuclear VCAM1 locus respectively. As elevated levels of
exogenous VEGF-A stimulation can promote new Tpl2
synthesis this could then potentiate the endothelial response to
diverse ligands such as VEGF-A, CXCL1 or bFGF (Lee et al.,
2013). Different VEGF-A isoforms can bind the VEGFR2
receptor tyrosine kinase and activate multiple signal transduction
pathways with different cellular responses (Fearnley et al., 2016).
Previous work showing that VEGF-A isoform-specific signal
transduction via the canonical MEK1-ERK1/2 pathway causes
hyperphosphorylation of ATF-2 linked to VCAM-1 expression
(Fearnley et al., 2014a). It is well-established that the VEGFA gene
encodes multiple isoforms which have significant differences in
signaling properties and cellular responses (Fearnley et al., 2015,
2014a, 2016; Harper and Bates, 2008; Kawamura et al., 2008a,
2008b; Pan et al., 2007).
VEGF-A and Tpl2 in disease
There is much debate on whether Tpl2 functions as a proto-
oncoprotein and/or tumor suppressor (Lee et al., 2015;
Vougioukalaki et al., 2011). Our study shows that Tpl2 has basal
and ligand-stimulated properties which could potentially have
different consequences in health or disease. A recent study suggests
that Tpl2 levels are strongly linked to colorectal cancer (CRC) (Pyo
et al., 2018). CRC is a disease strongly linked to dysregulation
of the VEGF-VEGFR axis, with therapies aimed at targeting both
soluble VEGF-A (Los et al., 2007) and membrane-bound VEGFRs
(Morabito et al., 2006). A high proportion (∼40%) of CRC patients
displayed high Tpl2 levels and frequent distant metastases
(Pyo et al., 2018). These lines of evidence suggest that a
functional link between VEGF-A and Tpl2 regulates serious
disease states such as CRC.
Tpl2 kinase inhibitors can have therapeutic capability in
pro-inflammatory disorders such as rheumatoid arthritis and
Fig. 5. Tpl2 modulates eNOS
phosphorylation and endothelial
cell permeability. (A) Immunoblot
analysis of control, scrambled or
Tpl2-specific siRNA-treated
endothelial cells to assess
VEGFR2, eNOS, Akt and Tpl2
status. Quantification of immunoblot
data for levels of (B) Akt-pS473 and
(C) eNOS-pS1177 levels. Error
bars indicate ±s.e.m. (n≥3).
In panels B and C, statistical
tests=one-way ANOVA; **P<0.01.
(D–E) Assessment of endothelial
cell permeability by measuring
trans-endothelial electrical
resistance (TEER) on control,
scrambled or Tpl2-depleted
endothelial cells under (D) basal
conditions in serum-free MCDB131
media, or (E) with addition of
VEGF-A (25 ng/ml). High TEER
values correspond to reduced cell
monolayer permeability indicative
of more stable cell–cell junctions.
Horizontal red dotted and blue
dashed lines depict baselines for
control/scrambled or Tpl2-depleted
cells respectively. Error bars
indicate ±s.e.m. (n=3). In panels D
and E, statistical tests=two-way
ANOVA; *P<0.05, **P<0.01,
***P<0.001.
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inflammatory bowel disease (Gantke et al., 2011; Hall et al., 2007;
Vougioukalaki et al., 2011). As our study suggests that endothelial
Tpl2 is required for multiple aspects of endothelial cell function,
homeostasis and angiogenesis, therapeutic strategies based on
pharmacological inhibition of Tpl2 need caution. Despite using a
combination of siRNA and pharmacological inhibition to validate
our results, we do see some discrepancies between the two
different approaches. In this context, single siRNA duplex use or
rescue experiments using an RNAi-resistant Tpl2 construct could
provide more insights. Furthermore, the current study lacks a Tpl2
kinase assay to confirm that the Tpl2-selective inhibitor was
indeed targeting Tpl2 kinase activity within the cell. Further work
is thus required to strengthen the importance of Tpl2 as a central
regulator of endothelial responses. Nonetheless, our findings
now provide a model for endothelial Tpl2 function (Fig. 8) which
could be useful for better understanding cancer and immune
dysfunction.
MATERIALS AND METHODS
Antibodies, reagents and growth factors
Antibodies: goat-anti-VEGFR2 cat. #AF357, mouse-anti-VCAM-1 cat.
#BBA5 (R&D Systems, Minneapolis, MN, USA), goat-anti-nectin 2 cat.
#AF2229 (R&D Systems), rabbit-anti-ATF-2 cat. #35031, rabbit-anti-
phospho-ATF-2 cat. #9221 (pT71), rabbit-anti-phospho-VEGFR2-Y1175
(pY1175) cat. #2478 (Cell Signaling Technology, Danvers, MA, USA),
goat anti-VE-cadherin, cat. #sc-6458, mouse-anti-PECAM-1 (CD31) cat.
#sc-65260, mouse-anti-Tpl2 cat. #37677 (Santa Cruz Biotechnology,
Dallas, TX, USA), mouse-anti-PVR (SKII.4) cat. #132202 (BioLegend,
San Diego, CA, USA), mouse-anti-α-tubulin, (Sigma-Aldrich, Poole, UK).
Endothelial cell growth medium (ECGM) cat. #C-22110 and recombinant
human VEGF-A165 cat. #64423 was from PromoCell (Heidelberg,
Germany). Tpl2 kinase inhibitor (CAS 871307-18-5) cat. #616373 was
purchased from Calbiochem (San Diego, CA USA), ERK1/2 (PD98059)
cat. #P-4313, p38 MAPK (SB203580) cat. #S-3400 and JNK (SP600125)
cat. #S-7979 inhibitors were purchased from LC Laboratories (Woburn,
MA, USA) and Akt (MK2206) cat. #A10003 inhibitor was purchased from
AdooQ BioScience (Irvine, CA, USA).
Fig. 6. Tpl2 modulates endothelial cell adhesion. Endothelial cells were subjected to controls scrambled siRNA duplex treatment (Scr RNAi) or
Tpl2-specific siRNA duplex (Tpl2 RNAi) and analyzed by confocal laser microscopy. (A) Endothelial cells subjected to RNAi were fixed and stained for
cell-surface adhesion proteins such as VE-cadherin, PVR and PECAM-1. Arrows indicate cells showing increased staining for VE-cadherin and PECAM-1
under conditions of Tpl2 knockdown. Scale bar: 20 µm. (B) Endothelial cells subjected to RNAi were fixed and stained for Nectin 2, PVR and PECAM-1.
Arrows indicate cells showing increased staining for F-actin and PECAM-1 upon Tpl2 knockdown.
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Fig. 7. Probing the link between Tpl2, Akt activation and ATF-2 status. (A) Immunoblot analysis of endothelial cells titrated with Tpl2-selective kinase
inhibitor (2–50 µM, 4 h). Quantification of immunoblot data upon inhibitor titration on activated kinases such as (B) Akt-pS473, (C) ERK1/2-pT202/pY204,
(D) p38 MAPK-pT180/pY182 and (E) JNK-pT183/pY185. Error bars indicate ±s.e.m. (n=3). In panels B–E, statistical tests=one-way ANOVA; *P<0.05.
(F) Immunoblot analysis of endothelial cells treated with small molecule kinase inhibitors (2 µM, 30 min) specific for ERK1/2 (PD98059), p38 MAPK
(SB203580), JNK (SP600125) and Akt (MK2206). (G) Quantification of immunoblot data for relative ATF-2-pT71 levels upon inhibition of different protein
kinases. Error bars indicate ±s.e.m. (n=3).
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Cell culture and immunoblotting analysis
Human umbilical vein endothelial cells (HUVECs; PromoCell, Heidelberg,
Germany) were grown and characterized as previously described (Fearnley
et al., 2014b). Cells were seeded into six-well plates and cultured in ECGM
until∼80% confluent, cells werewashed twicewith PBS and starved in ECGM
for 24 h. If required HUVECs were treated with the desired concentration of a
small molecule kinase inhibitor or stimulated with VEGF-A (25 ng/ml). Cells
were washed twice with ice-cold PBS, lysed in 2% (w/v) SDS, TBS, 1 mM
PMSF and protease inhibitor cocktail cat. #P8340 (Sigma-Aldrich). Protein
concentration was determined using the bicinchoninic acid (BCA) assay cat.
#23227 (Thermo Fisher Scientific, Loughborough, UK). 20 µg of protein
lysate was subjected to SDS-PAGE before transfer onto nitrocellulose
membrane and analysis via immunoblotting.
Quantitative reverse transcription polymerase chain reaction
(qRT-PCR)
HUVECs were serum starved for 2 h prior to stimulation with VEGF-A
(25 ng/ml) for 1.5 h or 3 h. Total RNA was then extracted using RNeasy
Plus Mini Kit cat. #74134 (Qiagen, UK). 1 µg total RNA was reverse
transcribed using GoScript Reverse Transcription System cat. #A6001
(Promega, UK). Real time quantitative reverse transcription PCR was
performed using Power SYBR Green master mix cat. #4368702 (Applied
Biosystems, Warrington, UK) with following primer sets: GAPDH
(endogenous control), forward primer 5′–GTC TCC TCT GAC TTC
AACAGCG−3′, reverse primer 5′–ACCCTGTTGCTGTAGCCAA−3′;
Tpl2, forward primer 5′–CGC AAG AGG CTG AGTA−3′, reverse primer
5′–TTC CTG TGC ACG AAG AAT CA−3′. qRT-PCR was carried out in
multiwell plates run on an ABI 7900HT Fast Real-Time PCR System
(Applied Biosystems). Gene expression was analyzed using the delta-delta
Ct method standardized against an endogenous control, GAPDH.
Lipid-based transfection of siRNA duplexes
HUVECs were transfected with siRNA duplexes using Lipofectamine
RNAiMAX cat. #13778075 (Thermo Fisher Scientific). Per well of a
six-well plate, 15 µl of 2 µM siRNA duplexes (20 nM final concentration)
were added to 481 µl of serum/antibiotic-free OptiMEM cat. #31985070
(Thermo Fisher Scientific), briefly inverted and incubated at room
temperature (RTP) for 5 min. 4 µl of Lipofectamine was then added
and the mixture inverted briefly, before incubation at RTP for 20 min.
2.5×105 cells/ml were seeded in 1 ml volume of OptiMEM, followed by
immediate dropwise addition of the siRNA/lipofectamine mixture. Cells
were left at RTP for 30 min before being returned to the incubator. After 6 h,
media was replaced for ECGM. Cells were allowed to recover for 72 h prior
to treatment or processing for analysis.
Fig. 8. Schematic showing a role for Tpl2 in endothelial function the cellular response to VEGF-A. Step 1: VEGF-A stimulation promotes increased
Tpl2 expression and activation via an unknown transcription factor (TF-X). Step 2: Tpl2 maintains phosphorylation of residue T71 on ATF-2 stabilizes ATF-2
levels. Step 3: VEGF-A-stimulated hyperphosphorylation of residue T71 on ATF-2 stimulates VCAM-1 gene transcription leading to increased VCAM-1 levels
and increased endothelial-leukocyte interaction. Step 4: basal Tpl2 activity promotes phosphorylation of residue S473 on Akt, causing Akt activation leading
to eNOS-S1177 phosphorylation. Step 5: eNOS phosphorylation and activation leads to NO production and increased endothelial cell permeability. Grey
arrows depict undefined mechanism.
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Tubulogenesis assay
Primary human foreskin fibroblasts cat. #C-12350 (Promocell) were
cultured in 48-well plates in DMEM containing 10% (v/v) FCS, 1% (v/v)
non-essential amino acids and 1% (v/v) sodium pyruvate until confluent.
7500 HUVECs were seeded onto the fibroblasts monolayer in a 1 ml 1:1
mixture of DMEMcontaining 10% (v/v) FCS, 1% (v/v) non-essential amino
acids and 1% (v/v) sodium pyruvate and ECGM. Cells were left to
acclimatize for 24 h. Media was aspirated and replaced with fresh ECGM
±VEGF-A (25 ng/ml) ±Tpl2 kinase inhibitor (2 µM) as desired; media
was replaced every 2–3 days for 7 days. Co-cultures were fixed in 200 µl
10% (v/v) formalin for 20 min and blocked in 5% (w/v) BSA for 30 min at
RTP. Co-cultures were then incubated with 1 µg/ml mouse anti-human
PECAM-1 (CD31) overnight at 4°C. Cells were washed three times with
PBS prior to incubation with donkey anti-mouse Alexa Fluor 594 conjugate
cat. #R37115 (Thermo Fisher Scientific) for 3 h at RTP. Wells were
washed three times with PBS. Endothelial tubules were visualized via
immunofluorescence microscopy using an EVOS-fl inverted digital
microscope (Thermo Fisher Scientific). Three random fields were imaged
per well. Total tubule length was then quantified from each photographic
field using the open source software AngioQuant (www.cs.tut.fi/sgn/csb/
angioquant) and values averaged. For a more detailed method please see
Fearnley et al. (2014b).
Leukocyte binding assay
2×105 HL-60 leukocytes/well were labelled with 0.5 µg/ml calcein cat.
#C3100MP (Thermo Fisher Scientific) for 30 min at 37°C. Cells
were pelleted and washed twice in 5 ml RPMI+10% (v/v) FCS.
De-esterification of the calcein reagent was then left to occur for 30 min
at 37°C. Cells were then incubated with 100 nM phorbol 12-myristate
13-acetate cat. #P1585 (PMA; Sigma-Aldrich) for 30 min at 37°C. Cells
were pelleted and washed twice in 5 ml RPMI. 2×105 HL-60 leukocytes/
well were then added onto a confluent HUVEC monolayer, which
had been previously stimulated with full growth media (±25 ng/ml
VEGF-A for 7 h) and left to adhere for 1 h at 37°C. Non-adhered
leukocytes were removed via gentle rinsing with PBS. Bound leukocytes
were visualized and photographed via immunofluorescence microscopy
using an EVOS-fl inverted digital microscope, before cells were lysed in
200 µl RIPA buffer. 50 µl of cell lysate was then analyzed via fluorescence
excitation at 488 nm and emission at 520 nm in a multiwell plate
format using a 96-well FLUOstar OPTIMA florescence plate reader
(BMG LABTECH, Buckinghamshire, UK). Values were compared to
non-stimulated controls.
MTS cell viability assay
3000 HUVECs were seeded per well of a 96-well plate and cultured in 90 µl
ECGM overnight. 10 µl of MTS reagent (CellTiter 96 AQueous Non-
Radioactive Cell Proliferation Assay cat. #G5421; Promega, Madison,
USA) was added to each well after 20 h. After further incubation for 4 h, we
monitored the color change caused by reduction of the yellow tetrazolium
compound (MTS) by metabolically active cells to brown formazan. Change
in color was monitored at 490 nm using a Tecan Sunrise multi-wavelength
96-well plate reader (Mannedorf, Switzerland).
Ex vivo aortic sprouting assay
All procedures involving animals and their tissues were carried out in
accordance to UK Home Office regulations and guidance at RTP unless
otherwise stated. Male 8–9-week-old wild-type C57BL/6 mice were
euthanized and the thoracic aorta was harvested from aortic arch to
diaphragm. Cleaned aortas were sliced into 0.5 mm rings and serum
starved overnight at 37°C in 5 ml OptiMEM containing penicillin-
streptomycin. Aortic rings were embedded into 55 µl of type 1 rat tail
collagen cat. #08-115 (Millipore, Watford, UK) in 96-well plates and
stimulated with 150 µl OptiMEM containing 2.5% (v/v) FCS and
penicillin-streptomycin ±VEGF-A (25 ng/ml), in the presence or
absence of a Tpl2 kinase inhibitor (2 µM). Aortic rings were incubated
at 37°C for 5–7 days with a media change on day 3 and 5. Rings were then
washed, permeabilized and blocked as previously described (Baker et al.,
2012). 2.5 µg BS-I lectin-FITC cat. #L2895 (Sigma-Aldrich) in PBLEC
was then added per well and incubated 6 h at RTP. 1 µg/ml DAPI (in
PBLEC) was then added per well for 2 h at 37°C. Aortic sprouts were the
visualized and imaged using an EVOS-fl inverted digital microscope.
Number of initial sprouts (vascular sprouts emanating directly from the
aortic ring) were counted and average.
Assessment of endothelial monolayer permeability using
trans-endothelial electrical resistance (TEER)
Human endothelial cells were seeded in 450 µl at 1.5×105 cells/well
(sufficient to give a monolayer) into a 0.4 µm pore size Corning Transwell
filter cat. #CLS3397 (Sigma-Aldrich) inserted into a 24-well plate
containing 500 µl ECGM and left to adhere overnight. At t=0 h the trans-
endothelial electrical resistance (TEER) across each monolayer was
measured using Millicell-ERS device cat. #MERS00002 (Millipore).
Then 50 µl of media MCDB131+0.2% (w/v) BSA ±VEGF-A (25 ng/ml)
was added to the upper chamber. After a further 1, 2, 4, 6 or 8 h the TEER
across each monolayer was measured again and the relative increase in
permeability (corresponding to a decrease in electrical resistance across the
endothelial monolayer) was calculated as follows: relative TEER
(%)=(TEER of sample of interest–TEER of blank (TEER across insert
with no cells)/TEER of control cells at 0 h–blank)×100.
Statistical analysis of experimental data
This was performed using a one-way analysis of variance (ANOVA)
followed by Tukey’s post-hoc test or two-way ANOVA followed by
Bonferroni multiple comparison test using GraphPad Prism software
(La Jolla, USA). Significant differences between control and test groups
were evaluated with P-values less than 0.05 (*), 0.01 (**), 0.001 (***) and
0.0001 (****) indicated on the graphs. Error bars in graphs and histograms
denote ±s.e.m.
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